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Background
In developed counties the rates of non-AIDS defining
cancers (NADCs) now exceed those of AIDS-defining
cancers in HIV-positive patients. Drug-drug interactions
between HAART and chemotherapy may complicate the
treatment of patients with NADCs. In order to deter-
mine the proper dosing of new targeted chemotherapies
in patients with NADCs who are also on HAART, the
AMC is performing a series of phase I/pharmacokinetic
(PK) studies to determine the proper dosing of these
agents in HIV+ cancer patients. We present the results
of the first such study which investigated sunitinib, an
oral multiple tyrosine kinase inhibitor.
Methods
Patients with HIV and cancers refractory to standard ther-
apy were stratified into two arms: (1) non-ritonavir based
HAART or (2) ritonavir-based HAART. Six patients were
to be enrolled on arm 1 and receive the standard dose of
sunitinib (50mg po qd). Arm 2 used a phase I, 3+3 dose
escalation design (25, 37.5, and 50mg po qd). Cycles were
4 weeks on/2 weeks off. PK monitoring of sunitinb and its
active metabolite (S-M) were performed throughout cycle
one, and normalized based on dose level, to calculate
AUC0-24,C max, and trough level.
Results
Between 8/09 and 4/11, 19 patients were enrolled and
completed cycle 1 (10 on arm 1, 9 on arm 2). Cancer types
included Kaposi’s Sarcoma (7), lung (2), anal (2), head and
neck (2), NHL (1), and other solid tumors (5). Median
cycles was 2 (range 1-7). Following enrollment of the first
6 patients to Arm 1, that arm was expanded to include 3
additional patients on efavirenz, a potent inducer of
CYP3A4, to better characterize sunitinb-efavirenz interac-
tions. Patients on arm 1 tolerated standard treatment of
50mg with no dose limiting toxicities (DLTs). In the rito-
navir arm, three patients tolerated 25mg with no DLTs. At
the 37.5mg level, one patient had a DLT (wound dehis-
cence) and another three of five patients experienced
Grade 3 neutropenia. With 4 of 6 patients experiencing
grade 3/4 toxicity, enrollment was stopped, and no further
dose escalation was attempted. No patient had a CR or
PR, but five patients (26%) had stable disease for >4 cycles.
Grade 3/4 toxicities during cycle 1 were: neutropenia
(16%), leukopenia (16%), wound complications (5%), and
abdominal pain (5%). PK analysis showed significant inter-
patient variability of sunitinib and S-M. There were no PK
alterations of sunitinib between the arms, but there were
significant alterations in the PK of S-M. Efavirenz resulted
in a 220% increase, whereas ritonavir caused a 69%
decrease in the AUC of S-M, respectively.
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The recommended dose of suninitib for patients on rito-
navir is 37.5mg, whereas patients on NNRTI-based ther-
apy can be treated with the standard dose of 50mg per
day.
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